gpt-dict.com

紫檀芪 Pterostilbene × 血膽固醇

結論：台灣市場資訊黑箱

現有人體 RCT 證據一致指向紫檀芪對血膽固醇為「反向／有害」方向，而非無效（Riche 2014 在高膽固醇族群 LDL +17.

U ⚫ U 未驗證 台灣法規禁言 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 ⚠️ COI（產業聯盟資助） 💊 檢驗 / 藥物交互作用

現有人體 RCT 證據一致指向紫檀芪對血膽固醇為「反向／有害」方向，而非無效（Riche 2014 在高膽固醇族群 LDL +17.1 mg/dL, p=0.001；Brenner 2019 letter 再分析 Dellinger 2017 NRPT trial 顯示劑量相依 LDL 上升，直接導致 ChromaDex 主動下架紫檀芪產品）。

L1 Examine 15 個血脂相關 outcome 全部 F-grade「Small Detriment」（TC/LDL/HDL 三者皆惡化），L2 stance=harm，L5a NIH 將其列為「evidence not supportive (adverse)」，L9 直接把它列為 statin 的 moderate-severity 對抗性交互作用。

唯一未複製不利訊號的 Silbinol 2023（健康正常血脂族群、植物萃取、非純單體、安全性試驗）族群與劑量都不可外推到目標適應症。

判 D（反證據）而非 U（未驗證）：研究雖少（6 篇）但方向一致且機轉一致（PCSK9/SREBP2/LDLR 訊號），且已觸發業界自主下架的真實世界回應。

⚖️

評分透明度

所有分數由 7 層證據引擎計算，過程公開可查
原始分數 0.39
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
U · 台灣法規禁言
信心度
77%
證據方向大致一致
證據層級
E6
多篇較小型隨機對照試驗

各層「支持此療效」的程度

分數越低＝該層越不支持
L1 Examine國際基準
0.10
L11 AI 複核獨立判讀
0.30
L2 PubMed原始文獻
0.40
L3 機轉生理合理性
0.50
L5 臨床機構權威立場
0.50
不支持 中性 / 混合 支持
▸查看完整決策路徑（audit trail）
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.39
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative；實際 E6)
  5. detect_disputes — 偵測到 0 個 hard + 2 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial (Riche)
PMID: 25057276 2014 RCT (double-blind) n = 80
結論：Pterostilbene monotherapy SIGNIFICANTLY INCREASED LDL by 17.1 mg/dL (p=0.001); LDL rise was attenuated/abolished when combined with grape extract (p=0.47) and when subjects were on baseline statin therapy. BP reduced (SBP -7.8, p<0.01; DBP -7.3, p<0.001).
⚠️ 廠商資助 效應量：LDL MD +17.1 mg/dL (p=0.001) — adverse direction for cholesterol endpoint
前往 PubMed
Analysis of safety from a human clinical trial with pterostilbene (Riche, companion safety paper)
PMID: 23431291 2013 RCT (double-blind) n = 80
結論：Pterostilbene generally safe up to 250 mg/day on biochemical safety markers; no adverse signal on liver/kidney/glucose; but does not refute the LDL-raising effect reported in the companion efficacy paper.
⚠️ 廠商資助
前往 PubMed
Pterostilbene raises low density lipoprotein cholesterol in people (Brenner & Boileau, letter)
PMID: 30482564 2019 Cross-sectional
結論：Letter (Clin Nutr) argues NR+pterostilbene combination produces a DOSE-DEPENDENT, statistically significant rise in total cholesterol driven entirely by LDL-C increase, replicating the Riche 2014 signal; ChromaDex subsequently halted new pterostilbene orders.
⚠️ 廠商資助 效應量：Re-analysis of Dellinger 2017 data: dose-dependent LDL-C rise (specific delta not in abstract; reported in supplementary of cited trial)
前往 PubMed
Repeat dose NRPT (nicotinamide riboside + pterostilbene) increases NAD+ levels in humans safely and sustainably (Dellinger / Elysium Basis)
PMID: 29184669 2017 RCT (double-blind) n = 120
結論：Primary endpoint: NAD+ increased ~40% (1X) and ~90% (2X). Main paper reports overall safety; Brenner 2019 re-analysis flagged a dose- and time-dependent LDL-C INCREASE in NRPT arms not seen with NR alone, consistent with pterostilbene-driven effect.
⚠️ 廠商資助 效應量：LDL-C increase dose-dependent (re-analysis); main paper p-values for LDL not in abstract
前往 PubMed
A Short-Term Safety Evaluation of Silbinol(R) (Pterocarpus marsupium extract, 90% pterostilbene) in Healthy Adults
PMID: 37671486 2023 RCT (double-blind) n = 60
結論：Lipid profile (TC, LDL, VLDL, TG) remained WITHIN NORMAL RANGE in all participants with no significant between-group difference vs placebo; no adverse signal on LDL at 200 mg/day in healthy subjects over 8 weeks. Does not replicate Riche 2014 LDL rise, but enrolled different population (healthy normolipidemic vs hypercholesterolemic) and lower dose.
⚠️ 廠商資助 效應量：No significant lipid change (p-values not in abstract)
前往 PubMed
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial
PMID: 36082508 2023 RCT (double-blind) n = 111
結論：Primary endpoint (hepatic fat) not significantly different vs placebo; reduced hepatic inflammation markers. Abstract does not report LDL-C changes specifically; longer 6-month NRPT exposure trial provides additional cardiometabolic safety signal but no published meta-analysis yet aggregates LDL data.
⚠️ 廠商資助
前往 PubMed

L4a US FDA
謹慎
There were no records found that match your search criteria in this inventory. 來源↗
L4b EU EFSA
謹慎
Pterostilbene (Pterocarpus santalinus) extract (≥ 99%) ... assessed as novel and not authorized for use in food or food supplements unless a pre-market novel food authorisation is granted. 來源↗
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
未表態
— 本適應症無對應資料
L4e WHO
謹慎
Pterostilbene — CAS 537-42-8 — listed in Health Canada Natural Health Products Ingredients Database (NHPID) as an approved Schedule 1 'isolate' ingredient; source organism cited as Pterocarpus marsupium (stem heartwood). Multiple NPN-licensed products in the LNHPD (e.g. Nutracentials Blueberry Pterostilbene NX, NPN 80052455, containing pTeroPure® pterostilbene 25 mg; Ensonkan NMN+PQQ+Pterostilb… 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽

PTT（FITNESS/Doctor-Info/medstudent 等）、Dcard、Mobile01 均查無「紫檀芪」用於「血膽固醇」的鄉民實測討論。僅出現的中文內容為境外/直銷與業配來源（如 Viiva 美商惟哇、安禾團隊、s-cell.hk），泛談抗氧化、抗衰老、降血脂功效，並非台灣社群真實使用經驗。少數膽固醇相關 PTT 討論串完全未提及紫檀芪。屬冷門成分，無在地社群聲量。

💬社群實感

無共識（台灣社群無相關討論）

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

紫檀芪 50mg 提升 NAD+

代表來源 ↗
L10b · TFDA 法定身份 官方認定

紫檀芪是被台灣食藥署歸為藥用成分

來源 ↗

  • 心臟健康飲食型態
  • 生活型態調整（規律運動、健康體重、戒菸）
  • 史他汀類降血脂藥物
✓ PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v6 engine_version: v1.0 claim_id: CLM-COND-cholesterol-INT-pterostilbene-001
查看 ClaimReview 結構化資料 (JSON-LD) 
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-cholesterol-INT-pterostilbene-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "紫檀芪能改善血膽固醇",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "alternateName": "證據不足 (Insufficient evidence)"
  }
}